Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer [Phase 2]
A Phase 2 study is evaluating SDX-7320 with Eribulin for breast cancer, including metastatic triple-negative breast cancer. The trial is cur…
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment [Phase 3]
Phase 3 clinical trial evaluating toripalimab in combination with nab-paclitaxel for metastatic or recurrent triple-negative breast cancer h…
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC) [Phase 1, Phase 2]
MD Anderson is running a Phase 1/2 trial to evaluate the combination of Naxitamab and Sacituzumab Govitecan in metastatic triple-negative br…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases [Phase 2]
A Phase II study is evaluating the combination of pembrolizumab and lenvatinib in patients with triple-negative breast cancer, non-small cel…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care [Phase 3]
A Phase III study comparing JSKN016 to physician's choice in patients with triple-negative breast cancer who have failed standard of care is…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: FUSCC Refractory TNBC Platform Study (FUTURE2.0) [Phase 2]
A Phase 2 clinical trial update for the FUTURE2.0 platform study at Fudan University in refractory triple-negative breast cancer, currently …
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Breast Cancer Evolution During Neoadjuvant Systemic Therapy
Update on a breast cancer neoadjuvant systemic therapy trial, currently recruiting and covering ER-positive, HER2-positive, and triple-negat…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors [Phase 1]
Phase 1 clinical trial update for Enzelkitug as a single agent and in combination with a checkpoint inhibitor in adults with locally advance…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: JS207 Combination Therapy in Triple-negative Breast Cancer [Phase 2]
Phase 2 trial of JS207 combination therapy for triple-negative breast cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Pilot Study of Aerobic Exercise During Immune Checkpoint Inhibitor Therapy in Early-Stage TNBC [NA]
Description of a pilot clinical trial evaluating aerobic exercise during immune checkpoint inhibitor therapy for patients with early-stage t…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer [Phase 2]
A Phase 2 clinical trial evaluates carboplatin and paclitaxel with or without panitumumab in invasive triple-negative breast cancer. The stu…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC)
An upcoming clinical trial is evaluating ovarian toxicity outcomes in patients with triple-negative breast cancer treated with immunotherapy…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: A Study of XMT-1660 in Participants With Solid Tumors [Phase 1]
Phase 1 study of XMT-1660 in participants with solid tumors is currently recruiting. The trial lists indications including triple-negative b…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Gemcitabine vs Paclitaxel in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer [Phase 2]
Phase 2 trial comparing gemcitabine to paclitaxel in metastatic triple-negative breast cancer among Caribbean women of African ancestry; cur…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Phase 1 Study of CLR 125 in Triple Negative Breast Cancer [Phase 1]
Phase 1 study of CLR 125 for triple-negative breast cancer is currently recruiting, representing an early clinical investigation by Cellecta…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients [Phase 2]
A Phase 2 clinical trial is evaluating whether vitamin D supplementation affects pathologic complete response rates in vitamin D-deficient p…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors [Phase 1]
Phase 1 study of LY4101174 in participants with recurrent, advanced or metastatic solid tumors is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer [Phase 1]
This Clinical Trial Update describes a Phase 1 study evaluating the addition of BAY 1895344 to standard chemotherapy (cisplatin or cisplatin…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours [Phase 1]
Phase 1 trial of GCAR1 CAR T-cell therapy for GPNMB-expressing solid tumors; study targets alveolar soft-part sarcoma, renal cell carcinoma,…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. [Phase 1, Phase 2]
A Phase I/II clinical trial is evaluating BLEX 404 in combination with docetaxel for advanced or metastatic triple-negative breast cancer; t…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer [Phase 1]
This clinical trial update reports testing the addition of berzosertib to radiation therapy in patients with chemotherapy-resistant triple-n…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer [Phase 2]
A Phase 2 trial evaluating serial circulating tumor DNA monitoring during adjuvant capecitabine in early triple-negative breast cancer is cu…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer [Phase 1]
Phase 1 clinical-trial update exploring adding ZEN003694 (ZEN-3694) and pembrolizumab to nab-paclitaxel for patients with locally advanced o…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan [Phase 1]
Phase 1 trial evaluating the safety, adverse events, and pharmacokinetics of Azirkitug alone or in combination with Budigalimab, Bevacizumab…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer [Phase 1]
Phase 1 trial testing the combination of ZEN003694 and Binimetinib in patients with advanced, metastatic, or unresectable solid tumors with …